| (USD) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 22.14M | — |
| Operating expense | — | — |
| Net income | 10.67M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, TPVG returned -3.5% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | -12.0% |
| 1 year | -3.5% |
| 5 years | -31.2% |
| 10 years | +64.5% |
| All-time high | $17.96 (Dec 2021) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what $1,000 in TPVG would be worth today ›Yes. TriplePoint Venture Growth BDC Corp. paid 4 dividends over the past 12 months. The most recent was $0.23 per share on Jun 16, 2026. The dividend yield is 14.10%.
TriplePoint Venture Growth BDC Corp. stock trades on NYSE under the ticker symbol TPVG.
TriplePoint Venture Growth BDC Corp. is part of the Financial Services sector.
TriplePoint Venture Growth BDC Corp. has a market cap of 214.54M USD, based on the latest quote.
TriplePoint Venture Growth BDC Corp. is expected to report earnings around Nov 4, 2026. That date is an estimate and has not been confirmed by the company.
TriplePoint Venture Growth BDC Corp. is a business development company specializing investments in venture capital-backed companies at the growth stage investments. It also provides debt financing to venture growth space companies which includes growth capital loans, secured and customized loans, equipment financings, revolving loans and direct equity investments. The fund seeks to invest in e-commerce, entertainment, technology and life sciences sector. Within technology the areas of focus include: Security, wireless communication equipments, network system and software, business applications software, conferencing equipments/services .big data, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, software, software as a service, and other technology related subsectors and within life sciences the areas of focus include: biotechnology, bio fuels/bio mass, diagnostic testing and bioinformatics, drug delivery, drug discovery, healthcare information systems, healthcare services, medical, surgical and therapeutic devices, pharmaceuticals and other life science related subsectors. Within growth capital loans it invests between $5 million and $50 million, for equipment financings it invests between $5 million and $25 million, for revolving loans it invests between $1 million and $25 million, and for direct equity investments it may invest between $0.1 million and $5 million (generally not exceeding 5% of the company's total equity). The debt financing products are typically structured as lines of credit and it invests through warrants and secured loans. It targeted returns between 10% and 18%. It does not take board seat in the company.
